Monoclonal Antibody Pipeline Focused on Oncology

Dedicated to developing treatments to significantly improve and/or extend the life of patients.

Learn More

Better Life Through Better Science

KaloBios is developing a proprietary portfolio of customized, targeted, first-in-class monoclonal antibodies designed to significantly improve the care of seriously ill patients with cancer.

Recent Corporate Highlights

  • Completed enrollment in 180 patient Phase 2 cystic fibrosis study for KB001-A
  • Initiated Phase 2 expansion portion of clinical trial for KB004 in hematologic malignancies
  • Announced preliminary Phase 1 results in advanced hematologic malignancies with KB004 at ASH Annual Meeting
  • KB001-A granted Fast Track Status in Pa pneumonia prevention
  • Received Orphan Drug designation from both the United States Food and Drug Administration (FDA) for KB001-A for the treatment of Pa lung infection in CF patients

Read All

Latest News

January 8, 2015

KaloBios Announces Retirement of David W. Pritchard, President and Chief Executive Officer

January 6, 2015

KaloBios Reports Top-Line Data for Phase 2 Study of KB001-A to Treat Pseudomonas Aeruginosa Lung Infections in Cystic Fibrosis Patients

December 1, 2014

KaloBios Elects Robert A. Baffi, BioMarin Senior Executive, to Board of Directors


Upcoming Events

February 3, 2015

KaloBios Announces Upcoming Investor Conference Participation (BIO CEO & Investor Conference and Leerink Partners 2015 Global Healthcare Conference)

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue